

January 30, 2026

To

BSE Limited
 Corporate Relationship Department
 25th Floor, P J Towers
 Dalal Street, Fort,
 Mumbai – 400 001

BSE Scrip Code: 524743

To

National Stock Exchange of India Ltd. Exchange
 Plaza, 5th floor
 Plot No. C/ 1, G Block,
 Bandra-Kurla Complex Bandra (E),
 Mumbai - 400 051

NSE Symbol: FISCHER

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 30th January, 2026

Pursuant to Regulation 30 & 33 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors have inter-alia approved and taken on record the following at its meeting held today (30/01/2026):

1. Financial Results:

Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Nine month ended 31/12/2025 in the format specified under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ('SEBI Listing Regulations'), together with a copy of the Limited Review Reports of M/s. Bilimoria Mehta & Co., Chartered Accountants, Mumbai for your records and for uploading in your website. The aforesaid Unaudited Financial Results are also uploaded on the Company's website www.fischermv.com

An extract of the aforesaid Unaudited Financial Results, in the manner prescribed under the SEBI Listing Regulations, is annexed herewith in **Annexure-1** and the same will be published in English and Telugu newspapers within the time stipulated.

2. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mr. Aravindkumar V, Company Secretary & Compliance Officer and Key Managerial Personnel (KMP) of the Company and its Wholly Owned Subsidiary- Time Medical International Ventures (India) Private Limited, has tendered his resignation with effect from 10/02/2026 the said position due to personal reasons and to pursue career opportunities outside the organization.

Mr. Aravindkumar V has informed us that there are no other reasons for his resignation other than those provided in the resignation letter. Details as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 are enclosed herewith as **Annexure-2**.

3. Pursuant to Regulation 30 read with Schedule III, Part A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company has approved the proposal for restructuring of shareholding in its Malaysian subsidiary, Fischer Hospitality Sdn. Bhd. (FHSB), whereby a Malaysian trustee shall hold 51% of the shareholding in FHSB on behalf of the Company, with the Company holding the remaining 49% directly; the Audit Committee has also reviewed and approved the said proposal. Details as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 are enclosed herewith as **Annexure-3**.

4. As per the advice of BSE Limited and National Stock Exchange of India Limited ("Stock Exchange"), the non-compliance of Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 due to delayed submission of Related Party Transactions for the half year ended on 30th September 2025 with the Stock Exchanges, the details of the fine levied were placed before the Board in their meeting held today. The Board in its meeting considered the matter and recognized that the non-compliance of provisions is not wilful on the part of Company and recommended that, going forward, all stock exchange disclosures should be filed at the earliest which will allow sufficient time to address any technical issues with the relevant officials at the stock exchanges. Additionally, the Board advised the management to ensure timely compliance in the future.

The Board Meeting commenced at 12:30 PM (IST) and concluded at 4:40 PM (IST) Please take on record.

Yours Truly,

Thanking You,

For **FISCHER MEDICAL VENTURES LIMITED**



ARAVINDKUMAR V

COMPANY SECRETARY AND COMPLIANCE OFFICER



 <p style="text-align: center;">FISCHER MEDICAL VENTURES LIMITED Regd Off: No.480/2, Andhra Pradesh Medtech Zone Limited, Nadupura Village, Pedagantyada Mandal, Nadupura, Visakhapatnam, Andhra Pradesh, India, 530044 Corp off: Level 8, Prestige Palladium Bayan, No. 129-140 Greaves Road, Chennai, Tamil Nadu, 600006, India Email: csg.fischermv.com Website: www.fischermv.com</p>													
Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 31.12.2025 pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.													
Rs. In Lakhs													
SL NO	PARTICULARS	STANDALONE						CONSOLIDATED					
		Quarter ended	Nine Months ended	Year ended	Quarter ended	Nine Months ended	Year ended	Quarter ended	Nine Months ended	Year ended	Quarter ended	Nine Months ended	
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
I	Revenue from Operations	131.50	742.69	-	1,328.42	-	521.97	10,109.52	8,630.53	1,174.85	21,084.52	6,152.45	11,069.87
II	Other Income	85.67	143.46	86.58	309.53	280.76	345.70	108.81	248.14	37.81	1,103.58	134.34	149.20
III	Total Income (I + II)	217.17	886.15	86.58	1,637.95	280.76	867.67	10,218.33	8,878.67	1,212.66	22,188.10	6,286.79	11,219.07
IV	Expenses	-	-	-	-	-	-	-	-	-	-	-	-
	Cost of Materials consumed	-	-	-	-	-	-	-	14.89	-	14.89	-	-
	Purchase of stock-in-trade	136.79	463.47	-	918.85	6.50	461.06	5,781.06	1,119.76	217.71	7,658.83	6,055.87	9,528.18
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(40.03)	-	-	(40.03)	(6.50)	(6.50)	(891.88)	133.52	536.19	(262.04)	(827.97)	(369.22)
	Employee Benefits Expense	61.81	45.46	2.90	149.03	9.61	12.84	416.77	374.75	74.64	1,107.29	164.55	258.13
	Direct Expenses	-	-	-	-	-	-	127.36	4,895.35	-	5,044.81	-	-
	Finance Costs	95.89	111.77	-	338.54	-	13.17	63.71	91.87	6.69	222.57	24.05	46.68
	Depreciation and amortisation expenses	8.16	8.16	2.75	24.48	2.86	12.72	77.01	51.37	55.71	205.35	112.25	163.28
	Other Expenses	104.71	119.47	19.18	280.98	59.31	278.30	2,519.71	466.76	296.71	3,312.72	678.64	1,321.11
	Total Expenses	367.34	748.33	24.83	1,671.85	71.78	771.59	8,093.74	7,148.26	1,187.65	17,304.42	6,207.39	10,948.16
V	Profit / (Loss) before Exceptional Items & Tax (III - IV)	(150.16)	137.82	61.75	(33.90)	208.98	96.08	2,124.59	1,730.41	25.01	4,883.69	79.40	270.92
VI	Share of profit/(loss) of Associates	-	-	-	-	-	-	(5.74)	(4.22)	(12.57)	(21.11)	(38.34)	(48.65)
VII	Exceptional Items	-	-	-	-	-	-	-	-	-	-	-	-
VIII	Profit / (Loss) before Tax (V - VI-VII)	(150.16)	137.82	61.75	(33.90)	208.98	96.08	2,118.85	1,726.19	12.44	4,862.58	41.06	222.27
IX	Tax Expense	-	-	-	-	-	-	-	-	-	-	-	-
	Current Tax	-	-	(42.00)	-	(54.00)	(57.40)	(172.25)	(275.14)	(42.00)	(889.01)	(54.00)	(107.95)
	Deferred Tax (Asset)/Liability	(16.77)	(54.05)	0.17	(110.21)	0.14	27.64	(23.12)	(61.47)	0.17	(159.68)	2.51	11.87
	Tax pertaining to Previous year	-	-	-	-	-	-	-	-	-	-	-	(5.40)
X	Profit / (Loss) for the period from continuing Operations (VIII-IX)	(166.93)	83.77	19.92	(144.11)	155.12	66.32	1,923.48	1,389.58	(29.39)	3,813.89	(10.42)	120.79
XI	Profit / (Loss) from Discontinued Operations	-	-	-	-	-	-	-	-	-	-	-	-
XII	Tax Expense of Discontinued operations	-	-	-	-	-	-	-	-	-	-	-	-
XIII	Profit / (Loss) from Discontinued Operations after Tax (XI - XII)	-	-	-	-	-	-	-	-	-	-	-	-
XIV	Profit / (Loss) for the period (X + XIII)	(166.93)	83.77	19.92	(144.11)	155.12	66.32	1,923.48	1,389.58	(29.39)	3,813.89	(10.42)	120.79
XV	Other Comprehensive Income	-	-	-	-	-	-	-	-	-	-	-	-
	A. Items that will not be reclassified to Profit / (Loss)	-	-	-	-	-	-	-	-	-	-	-	(0.78)
	(i) Remeasurement of defined benefit plan - Actuarial gains / (Losses)	-	-	-	-	-	-	-	6.32	-	6.32	-	(0.78)
	(ii) Income Tax relating on above	-	-	-	-	-	-	-	-	-	-	-	-
	(iii) Equity instruments through other comprehensive income	-	-	-	-	-	-	-	-	-	-	-	-
	Other Comprehensive Income-Total	-	-	-	-	-	-	-	6.32	-	6.32	-	(0.78)
XVI	Total comprehensive income for the period (comprising profit/Loss) for the period (after tax) and other comprehensive income for the period(after tax)	(166.93)	83.77	19.92	(144.11)	155.12	66.32	1,923.48	1,395.91	(29.39)	3,820.21	(10.42)	120.01
XVII	Paid up Equity Share Capital (Face Value Re.1/-)	6,485.15	6,485.15	5,350.00	6,485.15	5,350.00	6,380.15	6,485.15	6,485.15	5,350.00	6,485.15	5,350.00	6,380.15
XVIII	Other Equity excl. revaluation reserves as at previous balance sheet date	--	--	--	--	24,166.26	--	--	--	--	--	24,350.14	--
XIX	Earnings Per Share (EPS)	(0.03)	0.01	0.00	(0.02)	0.03	0.01	0.30	0.22	(0.01)	0.59	0.00	0.02
	(a) Basic EPS From Continuing Operations (In Rs.)	-	-	-	-	-	-	-	-	-	-	-	-
	(b) Basic EPS From Discontinued Operations (In Rs.)	-	-	-	-	-	-	-	-	-	-	-	-
	(c) Diluted EPS From Continuing Operations (In Rs.)	(0.03)	0.01	0.00	(0.02)	0.00	0.00	0.29	0.21	(0.01)	0.58	0.00	0.02
	(d) Diluted EPS From Discontinued Operations (In Rs.)	-	-	-	-	-	-	-	-	-	-	-	-
	Notes:	<p>1 The above financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as amended.</p> <p>2 The above unaudited Consolidated results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on January 30, 2026.</p> <p>3 The Statutory Auditor of the Company have carried out a Limited Review of the above Standalone and Consolidated Financial Results for the Quarter / Nine Months ended 31.12.2025 and their report was placed before the Board.</p> <p>4 On 28th July, 2025, the Board approved the sub division of Equity shares of Rs. 10/- into 10 equity shares of Re.1/- each by amending the capital clause of the Memorandum of Association. The shareholder's approval was obtained via postal Ballot on 30th August 2025. Effective from the record date of 12th September 2025, the authorized and Paid up share capital of the Company was split accordingly. Earnings Per Share (EPS) for the current and comparative periods has been proportionately adjusted and restated to ensure consistency and comparability.</p> <p>5 Figures for the previous periods have been reclassified, wherever necessary, to conform to the current period's classification.</p> <p>6 The Government of India has consolidated 29 existing labour legislations into four Labour Codes, namely the Code on Wages, 2019; the Code on Social Security, 2020; the Industrial Relations Code, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively, the "New Labour Codes"), which have been made effective from November 21, 2025.</p> <p>Based on management's assessment, the implementation of the New Labour Codes has not resulted in any material incremental impact on the Company's gratuity obligations. Accordingly, no adjustment has been made in the financial results for the quarter. The Company is evaluating the impact of the New Labour Codes on other areas, including the contract workforce. Management does not expect any material impact. The Company continues to monitor the issuance of relevant Central and State Rules and clarifications and will recognise the impact, if any, in the financial statements.</p> <p>7 The above is an extract of the detailed format of Quarterly / Half Year ended Unaudited Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly / Half Year ended Unaudited Standalone and Consolidated Financial Results are available in the Stock Exchange websites (www.nseindia.com and www.bseindia.com) and Company's website at www.fischermv.com</p>											
// BY ORDER OF BOARD //													
For Fischer Medical Ventures Limited													
 Mr. Ravindran Govindan Chairman & Managing Director													
Date : 30.01.2026													

Annexure-1

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) ('the Company') for the quarter ended 31st December 2025 and for the year to date results for the period 1 April 2025 to 31 December 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Bilimoria Mehta & Co,
Chartered Accountants
FRN.: 101490W**

A Mehta



**CA Aakash Mehta
Partner
Membership No: 165824**

Place: Mumbai

Date: 30-01-2026

UDIN: 26165824NQUWGH6947

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates (refer Annexure 1 for the list of subsidiaries and associates included in the Statement) for the quarter ended 31st December 2025 and consolidated year to date results for the period 1 April 2025, to 31st December 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1 /44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.


6. We did not review the interim financial results of subsidiaries included in the Statement, whose financial information reflects total assets of Rs 41,942.45 Lakhs as at 31st December 2025, and quarter ended total revenues of Rs 2,305.19 lakhs and quarter ended total comprehensive profit of Rs 468.48 lakhs, as considered in the Statement, in respect of an associate, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate is based solely on the review report of such other auditors.

7. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of Subsidiary, whose unaudited interim financial result includes the Group's share of net loss after tax of Rs. 112.90 Lakhs, and total comprehensive loss of Rs.112.90 Lakhs, for the quarter ended December 31, 2025 which has not been reviewed by any auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of the Associate, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group. Our conclusion on the statement in respect of matter stated above is not modified with respect to the financial result certified by the management.

Further, these subsidiaries and an associate, which are located outside India, whose interim financial results have been prepared in accordance with accounting principles generally accepted in their respective country and which have been reviewed by the other auditors under International Standards on Review Engagements (ISRE). The Holding Company's management has converted the financial results of such subsidiaries and an associate from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of these subsidiaries and an associate is based on the review reports of the other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

**For Bilimoria Mehta & Co,
Chartered Accountants
ICAI Firm Registration No.: 101490W**





CA Aakash Mehta
Partner
Membership No: 165824
Place: Mumbai
Date: 30-01-2026
UDIN: 26165824LQTECG8019

ANNEXURE-1

List of Entities included in the statement:

Sr no	Particulars	Stakes	Status
1	Time Medical International Ventures (India) Private Limited	100%	Subsidiary
2	Time Medical Philippines (Subsidiary of Time Medical International Ventures (India) Private Limited)	75%	Subsidiary
3	Blusim tech Pte Ltd. (Singapore)	20%	Associate of (Time Medical)
4	The Therapy Platform Pte Ltd (Singapore)	20%	Associate of (Time Medical)
5	FlynnCare HealthCare Innovations Private Limited	100%	Subsidiary of Fischer Medical Ventures Limited
6	Wondertech Medical Solutions Pvt Ltd	51%	Subsidiary of Fischer Medical Ventures Limited
7	Fischer Hospitality Sdn. Bdn.	60%	Subsidiary of Fischer Medical Ventures Limited
8	FMV International Ventures PTE Ltd.	100%	Subsidiary of Fischer Medical Ventures Limited
9	FMV HealthCare PTE Ltd.	100%	Subsidiary of Fischer Medical Ventures Limited
10	FMV Global Innovation PTE Ltd	100%	Subsidiary of Fischer Medical Ventures Limited

Details under Regulation 30 of the Listing Regulations read with SEBI Circular No. EBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Name	<i>Mr. AravindKumar V</i>
DIN	<i>NA</i>
Reason for Change	<i>Mr. AravindKumar V has tendered his resignation as Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company due to personal reasons.</i>
Date of cessation	<i>Closure of Business hours on 10th February 2026</i>
Term of appointment/reappointment;	<i>Not Applicable</i>
Brief profile (in case of appointment)	<i>Not Applicable</i>
Disclosure of relationships between Directors	<i>No relation with Directors</i>

Date: 20th January 2026

To,
The Board of Directors
Fischer Medical Ventures Limited

Survey No. 480/2 AP Medtech Zone, Nadupura Village,
Pedagantyadu Mandal,
Visakhapatnam, 530032

Respected Sir / Madam,

Subject: Resignation from the post of Company Secretary [Key Managerial Personnel] and Compliance Officer.

This is with reference to the above mentioned subject, I hereby tender my resignation from the post of Company Secretary [Key Managerial Personnel] and Compliance Officer of the Company, as I am seeking new opportunities for career growth.

I hereby request the Board to accept my resignation and release me from my role and responsibilities towards the Company as Company Secretary [Key Managerial Personnel] and Compliance Officer with effect from closure of business hours on 10th February 2026.

Further, I request you to file the necessary intimation / e-forms with the concerned regulatory authorities to give the effect of this resignation.

Thanking You

Yours Faithfully



Aravindkumar V
Membership Number A42531

Accepted


ANNEXURE III

Sr. no.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Fischer Hospitality Sdn. Bhd Turnover: Nil, since the Company is yet to commence its Business
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".	Fischer Hospitality Sdn. Bhd is the foreign subsidiary of the Company. Accordingly, Fischer Hospitality Sdn. Bhd is a related party.
3	Industry to which the entity acquired belongs	Investment Holding
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Not Applicable.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable.
6	Indicative time period for completion of the acquisition.	Not Applicable.
7	Nature of consideration - whether cash consideration or share swap and details of the same.	Cash Consideration
8	Cost of acquisition or the price at which the shares are acquired.	40 Shares of RM 1 each aggregating to RM 40

Sr. no.	Particulars	Details
9	Percentage of shareholding/ control acquired and/or number of shares acquired.	Existing - 60% Proposed - 40% Total -100%
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	Fischer Hospitality Sdn. Bhd. is a Malaysian private limited company incorporated in September 2024 and based in Melaka. Turnover: Not applicable since the Company was incorporated in FY 2024-2025 and it is yet to commence Business
